J. Goldman & Co’s Avadel Pharmaceuticals AVDL Stock Holding History

J. Goldman & Co’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,300	Closed	-$127K	–	461
2025 Q2	$127K	Buy	+14,300	New	+$126K	﹤0.01%	422
2024 Q4	–	Sell	-135,000	Closed	-$1.77M	–	459
2024 Q3	$1.77M	Buy	135,000 +132,700	+5,770%	+$2.02M	0.05%	241
2024 Q2	$32.3K	Buy	+2,300	New	+$37.5K	﹤0.01%	423
2024 Q1	–	Sell	-67,500	Closed	-$953K	–	414
2023 Q4	$953K	Buy	+67,500	New	+$793K	0.04%	232
2023 Q3	–	Sell	-108,000	Closed	-$1.78M	–	366
2023 Q2	$1.78M	Buy	+108,000	New	+$1.4M	0.06%	214

Other funds holding AVDL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's AVDL Position: Q4 2025 in Review

J. Goldman & Co sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 94,867 shares — an estimated $1.45M sold.

J. Goldman & Co first reported a position in AVDL in Q4 2014 and held it in 25 quarters. The position peaked at $13.9M in Q2 2016. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

J. Goldman & Co reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
J. Goldman & Co sold 94,867 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.45M.
J. Goldman & Co first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 25 quarters.
J. Goldman & Co's Avadel Pharmaceuticals position peaked at $13.9M in Q2 2016.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.